BCEL vs. GOVX, EVOK, ZVSA, SEEL, PHAS, LGVN, SNGX, ENSC, PTPI, and CYCC
Should you be buying Atreca stock or one of its competitors? The main competitors of Atreca include GeoVax Labs (GOVX), Evoke Pharma (EVOK), ZyVersa Therapeutics (ZVSA), Seelos Therapeutics (SEEL), PhaseBio Pharmaceuticals (PHAS), Longeveron (LGVN), Soligenix (SNGX), Ensysce Biosciences (ENSC), Petros Pharmaceuticals (PTPI), and Cyclacel Pharmaceuticals (CYCC). These companies are all part of the "pharmaceutical preparations" industry.
Atreca (NASDAQ:BCEL) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, community ranking and media sentiment.
GeoVax Labs has higher revenue and earnings than Atreca.
In the previous week, GeoVax Labs had 5 more articles in the media than Atreca. MarketBeat recorded 5 mentions for GeoVax Labs and 0 mentions for Atreca. GeoVax Labs' average media sentiment score of 0.47 beat Atreca's score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the news media.
37.5% of Atreca shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 11.3% of Atreca shares are held by company insiders. Comparatively, 5.7% of GeoVax Labs shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Atreca has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 2.91, indicating that its stock price is 191% more volatile than the S&P 500.
Atreca received 84 more outperform votes than GeoVax Labs when rated by MarketBeat users. However, 91.67% of users gave GeoVax Labs an outperform vote while only 67.86% of users gave Atreca an outperform vote.
GeoVax Labs has a consensus price target of $120.00, indicating a potential upside of 6,958.82%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs is more favorable than Atreca.
Atreca's return on equity of -157.90% beat GeoVax Labs' return on equity.
Summary
GeoVax Labs beats Atreca on 9 of the 14 factors compared between the two stocks.
Get Atreca News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
